This presentation is going to talk about the evolution of combination of target therapy and chemotherapy, standard regimens including anthracycline based, anthracycline-free and Taxane. For low risk patients or patients with comorbidities, how to balance between efficacy and side effect profile?

Last but not least, Dr. Tsai will talk about her insights on cancer treatment without chemotherapy. 

Due to the high prevalence rate of breast cancer, treatment of breast cancer has been a big topic over decades. The treatment paradigm of breast cancer shifts with time and medicine development, from CMF to Anthracyclines, and Taxane. We foresee more and more different classes of drugs would evolve and help too. 

This presentation will review the current treatment of early breast cancer and share insights on the pros and cons of different regimens based on clinical evidence.

Anthracyclines have been a mainstay of breast cancer therapy for decades, with strong evidence demonstrating their impact on breast cancer survival. Apart from the proven efficacy, associated toxicity has raised concern on the use of anthracyclines and turned the spotlight on anthracycline-free regimens.
This presentation will review the role of anthracyclines in treatment of early breast cancer and share insights on anthracycline-free regimen based on clinical evidence.

時間:2023年11月15日(三)18:50-21:00 ，地點:乳e學院線上直播

2023乳癌新知研討會，今年度共3場會議，將於6/30, 7/28, 8/30，改採線上課程進行，歡迎有意報考乳房專科醫師的學員及各位會員踴躍上網觀看影片!

HER2-low disease是最近常被提到的熱門字眼，起因於T-DXd憑藉DESTEINY-Breast04臨床試驗的成功，正式成為其標準治療之一。此次課程會複習HER2-low disease藥物研發的歷史、簡述現今HER2-low disease的臨床試驗概況、以及是否有其他的藥物也可在這個患者族群提供治療效益。